Janus Pharmaceuticals, Inc. Raises Series A Funding Of Over $2 Million; Funds To Be Used For Clinical Development Of Lead Compounds
10/19/2005 5:13:16 PM
LOS ANGELES--(BUSINESS WIRE)--April 12, 2005--Janus Pharmaceuticals Inc. (Janus) announced the closing of the company's Series A financing round for a total of over $2 million. Lead investor was Private Equity Japan Co., Ltd (PEJ). of Tokyo, Japan. Commensurate with this funding, Mr. Shinji Kimura, Managing Director, PEJ, joins the Janus Board of Directors.
Janus currently has three products in development, JA-001, a topical formulation of a widely studied antiviral product for the treatment of shingles (herpes zoster); JA-002, a gel formulation of a novel proprietary antibiotic targeting prevention and treatment of bacterial infections of the skin; and JA-003, an antibiotic cream for the treatment of acne. The proceeds of this funding will be used to complete milestone obligations and further product development activities including initiating Phase 1 clinical studies of JA-001 mid-year and filing an IND for JA-002 in Quarter 3 of 2005.
comments powered by